Lilly’s obesity franchise is executing at a level few large-cap drug companies ever reach. The decision is nevertheless HOLD: at $1,220.28 as of the 12 August 2026 close, investors are still paying for years of near-flawless volume growth, pricing resilience and pipeline delivery.

LLY — HOLD

Why now. This is a quiet-day re-underwrite of the 11 August 2026 thesis, not a response to new company evidence. Nothing fundamental has changed: Q2 2026 validated the growth engine, while the valuation continues to leave little room for ordinary execution slippage.¹²

The evidence. For the quarter ended 30 June 2026, revenue was $22.974bn, net income $7.095bn, and diluted EPS $7.94. Q2 2026 revenue grew 48% year over year, led mainly by Mounjaro and Zepbound volume, and management raised FY2026 revenue guidance to $85–87bn and adjusted EPS guidance to $35.50–36.50.¹² Foundayo’s 2026 FDA approval adds a once-daily oral GLP-1 that does not require fasting, expanding the convenience and primary-care opportunity.³⁴

The stock closed at $1,220.28 on 12 August 2026, down 0.9% from the $1,231.94 close on 10 August 2026 used in the original analysis.⁵ At the midpoint of FY2026 adjusted EPS guidance, the shares trade at roughly 33.9x FY2026 adjusted EPS as of 12 August 2026. That is defensible only if Lilly converts launch breadth and manufacturing scale into durable growth without a material hit to net pricing.²

Levels & triggers. I would move to ACCUMULATE below roughly $1,095, equivalent to about 30x the top end of FY2026 adjusted EPS guidance, provided the operating thesis remains intact. Confirmation requires Foundayo uptake and payer coverage, continued Zepbound/Mounjaro volume growth, and an on-time retatrutide filing in early 2027. The bull case breaks if FY2026 revenue falls below $85bn absent a short-lived supply disruption, or if obesity-franchise volume growth falls below 15% while net price is also declining.²

Horizon. This HOLD is for the next 12–18 months from 13 August 2026, through the Foundayo launch curve and the expected early-2027 retatrutide filing.

The bear case. The strongest objection is that Lilly’s category leadership could make today’s multiple look reasonable: Foundayo may expand the market rather than cannibalise injectables, and retatrutide could extend the efficacy frontier. But modest share loss, payer pressure, weaker persistence, or a pipeline delay can compress the multiple before revenue growth visibly slows. The balance sheet can fund the build—cash was $8.950bn at 30 June 2026, and operating cash flow was $16.023bn for the six months ended 30 June 2026—but funding capacity does not remove launch or pricing risk.¹

What I’m watching: Foundayo’s first payer-coverage and uptake signals, then Lilly’s next FY2026 guidance update; either could change the call.

Sources

Independent equity analysis, for information only, not investment advice.